Retatrutide
Price range: $90.00 through $300.00
Retatrutide is a groundbreaking, first-in-class triple-agonist peptide designed for comprehensive metabolic research. By simultaneously targeting the GLP-1, GIP, and Glucagon receptors, Retatrutide offers a synergistic “triple-action” approach to studying weight regulation, glucose homeostasis, and lipid metabolism. Each batch is rigorously processed to meet a 99% purity guarantee, ensuring that your research data remains precise and reproducible.
Description
Overview of Retatrutide
Retatrutide (LY3437943) represents the next frontier in peptide-based metabolic studies. While previous generations targeted one or two pathways, Retatrutide is engineered to activate three distinct hormone receptors. This unique pharmacological profile allows researchers to investigate the complex interplay between appetite suppression, insulin sensitivity, and resting energy expenditure within a single compound.
Triple-Action Research Applications
As a tri-agonist, Retatrutide provides a multi-faceted tool for studying:
-
GLP-1 Receptor Agonism: Researching delayed gastric emptying and central nervous system signaling related to satiety and appetite reduction.
-
GIP Receptor Agonism: Investigating the enhancement of nutrient-stimulated insulin secretion and potential protective effects against gastrointestinal sensitivity.
-
Glucagon Receptor Agonism: A key differentiator that allows for the study of increased energy expenditure and direct lipid metabolism (lipolysis) in the liver and adipose tissue.
Additional information
| Vial | 10MG, 20MG, 60MG |
|---|
